Feb 2014 allergy b clinical and aqhi
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Feb 2014 allergy b clinical and aqhi

on

  • 166 views

 

Statistics

Views

Total Views
166
Views on SlideShare
166
Embed Views
0

Actions

Likes
0
Downloads
2
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Feb 2014 allergy b clinical and aqhi Presentation Transcript

  • 1. Allergy B Clinical and AQHI Gimli Glider Pilot School/FMPE Abbotsford/Mission & Langley/Aldergrove 19 February & 25 February 2014
  • 2. Allergic Rhinitis 1. Small P, Frnkiel S, Becker A, et al. Rhinitis: A practical and comprehensive approach to assessment and therapy. Journal of Otolaryngology. 2007;36(Supl 1):S5-S27. ● The previous classification of seasonal or perennial Allergic Rhinitis is being replaced with intermittent and persistent Allergic Rhinitis1 ● Intermittent episode = symptoms last <6 weeks ● Persistent episode = symptoms last >6 weeks S O I R Sneezing E Nasal Obstruction Nasal Itch (pruritus) Nasal Rhinorrhea + Itchy Watery Eyes (conjunctivits) Allergic Rhinitis Diagnosis: 2 or More of ‘S O I R E’ Symptoms for More Than 1 Hour on Most Days
  • 3. Allergic Shiners The Patient with Allergies”: Franzese, CB, Burkhalter, NW. “The Patient with Allergies.” Medical Clinics of North America, 2010, 94 (5), pp. 891-902
  • 4. Allergic Faces
  • 5. Immunotherapy by allergen injections for seasonal allergic rhinitis ('hay fever') Seasonal allergic rhinitis ('hay fever') is a global health problem and its prevalence has increased considerably in the last two decades. Treatment includes allergen avoidance, drugs such as antihistamine tablets and nasal sprays, and immunotherapy (vaccination). For those patients whose symptoms remain uncontrolled despite drug treatment, specific allergen immunotherapy (SIT) is advised. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Immunotherapy by allergen injections for seasonal allergic rhinitis ('hay fever'). Cochrane Summaries. January 21, 2009 http://summaries.cochrane.org/CD001936/immunotherapy-by-allergen-injections-for-seasonal-allergic-rhinitis-hay-fever#sthash.7BSYsB2K.dpuf
  • 6. Immunotherapy by allergen injections for seasonal allergic rhinitis ('hay fever') Specific allergen immunotherapy is most commonly administered as subcutaneous (under the skin) injections by specialists requiring a building-up period followed by a maintenance period of 3 to 5 years. Immunotherapy may also be delivered by the oral, nasal or sublingual route and these will be studied in separate Cochrane reviews, as will immunotherapy for perennial (all year round) allergic rhinitis. In this review we aimed to evaluate the efficacy and safety of injection immunotherapy, compared with placebo, for reducing symptoms and the need for medication. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Immunotherapy by allergen injections for seasonal allergic rhinitis ('hay fever'). Cochrane Summaries. January 21, 2009 http://summaries.cochrane.org/CD001936/immunotherapy-by-allergen-injections-for-seasonal-allergic-rhinitis-hay-fever#sthash.7BSYsB2K.dpuf
  • 7. Immunotherapy by allergen injections for seasonal allergic rhinitis ('hay fever') We identified randomised, double- blind, placebo controlled trials of specific allergen immunotherapy in patients with seasonal allergic rhinitis due to tree, grass or weed pollens. 51 studies satisfied our inclusion criteria. In total there were 2871 participants (1645 in the treatment groups and 1226 in the placebo), each receiving on average 18 injections. The duration of treatment varied from three days to three years. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Immunotherapy by allergen injections for seasonal allergic rhinitis ('hay fever'). Cochrane Summaries. January 21, 2009 http://summaries.cochrane.org/CD001936/immunotherapy-by-allergen-injections-for-seasonal-allergic-rhinitis-hay-fever#sthash.7BSYsB2K.dpuf
  • 8. Immunotherapy by allergen injections for seasonal allergic rhinitis ('hay fever') • This review has shown that injection immunotherapy in suitably selected patients with hay fever results in significant reductions in symptom scores and medication use. Injection immunotherapy has a known and relatively low risk of severe adverse events. We found no long-term consequences from adverse events and no fatalities. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Immunotherapy by allergen injections for seasonal allergic rhinitis ('hay fever'). Cochrane Summaries. January 21, 2009 http://summaries.cochrane.org/CD001936/immunotherapy-by-allergen-injections-for-seasonal-allergic-rhinitis-hay-fever#sthash.7BSYsB2K.dpuf
  • 9. Immunotherapy by allergen injections for seasonal allergic rhinitis ('hay fever') Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Immunotherapy by allergen injections for seasonal allergic rhinitis ('hay fever'). Cochrane Summaries. January 21, 2009 http://summaries.cochrane.org/CD001936/immunotherapy-by-allergen-injections-for-seasonal-allergic-rhinitis-hay-fever#sthash.7BSYsB2K.dpuf
  • 10. Immunotherapy by allergen injections for seasonal allergic rhinitis ('hay fever')
  • 11. TABLE 1 | Potential mechanisms of antigen-specific therapy of allergy Rudolf Valenta; Nature Reviews Immunology 2, 446-453 (June 2002); http://www.nature.com/nri/journal/v2/n6/fig_tab/nri824_F1.html
  • 12. Allergy: the unmet need A blueprint for better patient care. A report of the Royal College of Physicians Working Party on the provision of allergy services in the UK. Royal College of Physicians June 2003. http://www.bsaci.org/pdf/allergy_the_unmet_need.pdf Basic Mechanisms: Immunization Replace IgE with IgG IgE IgG4
  • 13. Basic Mechanisms: Replace IgE with IgG FIGURE 3 | Proposed action of prophylactic allergy vaccines. Rudolf Valenta; Nature Reviews Immunology 2, 446-453 (June 2002); http://www.nature.com/nri/journal/v2/n6/fig_tab/nri824_F1.html
  • 14. Sublingual Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and Asthma s/l pill Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis (including hay fever). Cochrane Summaries. February 16, 2011. : http://summaries.cochrane.org/CD002893/sublingual-immunotherapy-for-allergic-rhinitis-including-hay-fever#sthash.3xD98siS.dpuf
  • 15. File:Illustration Phleum pratense0.jpg http://en.wikipedia.org/wiki/File:Illustration_Phleum_pratense0.jpg
  • 16. Product Monograph Description s/l tablet: 2800 BAU Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) is an allergy immunotherapy tablet for the treatment of signs and symptoms of grass allergy. PRODUCT MONOGRAPH: GRASTEK™ Standardized Allergenic Extract, Timothy Grass (Phleum pratense) ; Sublingual Tablet, 2800 BAU; Allergy Immunotherapy table; Submission Control No: 148335 ; Merck Canada Inc. Date of Preparation: December 12, 2013. http://www.merck.ca/assets/en/pdf/products/GRASTEK-PM_E.pdf
  • 17. Product Monograph Description s/l tablet: 2800 BAU The active substance is a natural grass pollen extract which is purified and standardized from Timothy Grass. PRODUCT MONOGRAPH: GRASTEK™ Standardized Allergenic Extract, Timothy Grass (Phleum pratense) ; Sublingual Tablet, 2800 BAU; Allergy Immunotherapy table; Submission Control No: 148335 ; Merck Canada Inc. Date of Preparation: December 12, 2013. http://www.merck.ca/assets/en/pdf/products/GRASTEK-PM_E.pdf
  • 18. Product Monograph Description s/l tablet: 2800 BAU It is formulated as an orally disintegrating tablet designed to rapidly dissolve under the tongue. Each sublingual tablet has a strength of 2800 BAU. PRODUCT MONOGRAPH: GRASTEK™ Standardized Allergenic Extract, Timothy Grass (Phleum pratense) ; Sublingual Tablet, 2800 BAU; Allergy Immunotherapy table; Submission Control No: 148335 ; Merck Canada Inc. Date of Preparation: December 12, 2013. http://www.merck.ca/assets/en/pdf/products/GRASTEK-PM_E.pdf
  • 19. A1. Indications and Clinical Use s/l tablet: 2800 BAU Indicated for reducing the signs and symptoms of moderate to severe seasonal Timothy and related grass pollen induced allergic rhinitis (with or without conjunctivitis) in adults and children 5 years of age and older [ages 5 to 65]. PRODUCT MONOGRAPH: GRASTEK™ Standardized Allergenic Extract, Timothy Grass (Phleum pratense) ; Sublingual Tablet, 2800 BAU; Allergy Immunotherapy table; Submission Control No: 148335 ; Merck Canada Inc. Date of Preparation: December 12, 2013. http://www.merck.ca/assets/en/pdf/products/GRASTEK-PM_E.pdf
  • 20. A2. Indications and Clinical Use s/l tablet: 2800 BAU 1. Confirmed by clinically relevant symptoms for at least 2 pollen seasons 2. and a positive skin prick test and/or a positive titre to Phleum pratense specific IgE; 3. and who have responded inadequately, or are intolerant to conventional pharmacotherapy. PRODUCT MONOGRAPH: GRASTEK™ Standardized Allergenic Extract, Timothy Grass (Phleum pratense) ; Sublingual Tablet, 2800 BAU; Allergy Immunotherapy table; Submission Control No: 148335 ; Merck Canada Inc. Date of Preparation: December 12, 2013. http://www.merck.ca/assets/en/pdf/products/GRASTEK-PM_E.pdf
  • 21. B1. Contraindications s/l tablet: 2800 BAU 1. Are hypersensitive to any of the excipients in the formulation or component of the Container. 2. Have previously had a severe systemic allergic reaction to Timothy or related grass immunotherapy. PRODUCT MONOGRAPH: GRASTEK™ Standardized Allergenic Extract, Timothy Grass (Phleum pratense) ; Sublingual Tablet, 2800 BAU; Allergy Immunotherapy table; Submission Control No: 148335 ; Merck Canada Inc. Date of Preparation: December 12, 2013. http://www.merck.ca/assets/en/pdf/products/GRASTEK-PM_E.pdf
  • 22. B2. Contraindications s/l tablet: 2800 BAU 3. Have unstable, severe chronic or severe seasonal asthma (FEV1 < 70% of predicted value after adequate pharmacologic treatment in adults; < 80% in children). PRODUCT MONOGRAPH: GRASTEK™ Standardized Allergenic Extract, Timothy Grass (Phleum pratense) ; Sublingual Tablet, 2800 BAU; Allergy Immunotherapy table; Submission Control No: 148335 ; Merck Canada Inc. Date of Preparation: December 12, 2013. http://www.merck.ca/assets/en/pdf/products/GRASTEK-PM_E.pdf
  • 23. Sublingual Tablet, 2800 BAU Efficacy • All studies included patients with concomitant asthma, but none included patients with severe or unstable asthma. Autoinjected epinephrine was provided to all patients enrolled in the US studies. Medscape Medical News: Grastek Recommended by FDA Panel for Timothy Grass Allergy; FDA Allergenic Products Committee Meeting. December 12, 2013 http://www.medscape.com/viewarticle/817771
  • 24. B3. Contraindications s/l tablet: 2800 BAU 4. Are taking β-blockers, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction PRODUCT MONOGRAPH: GRASTEK™ Standardized Allergenic Extract, Timothy Grass (Phleum pratense) ; Sublingual Tablet, 2800 BAU; Allergy Immunotherapy table; Submission Control No: 148335 ; Merck Canada Inc. Date of Preparation: December 12, 2013. http://www.merck.ca/assets/en/pdf/products/GRASTEK-PM_E.pdf
  • 25. B4. Contraindications s/l tablet: 2800 BAU 5. Have active inflammatory conditions in the oral cavity, e.g., oral lichen planus with ulcerations, severe oral candidiasis, dental extraction PRODUCT MONOGRAPH: GRASTEK™ Standardized Allergenic Extract, Timothy Grass (Phleum pratense) ; Sublingual Tablet, 2800 BAU; Allergy Immunotherapy table; Submission Control No: 148335 ; Merck Canada Inc. Date of Preparation: December 12, 2013. http://www.merck.ca/assets/en/pdf/products/GRASTEK-PM_E.pdf
  • 26. C1. Warnings and Precautions s/l tablet: 2800 BAU Treatment with 2800 BAU should only be prescribed and initiated by physicians with adequate training and experience in the treatment of respiratory allergic diseases. In case of pediatric treatment, the physicians should have the corresponding training and experience in children. PRODUCT MONOGRAPH: GRASTEK™ Standardized Allergenic Extract, Timothy Grass (Phleum pratense) ; Sublingual Tablet, 2800 BAU; Allergy Immunotherapy table; Submission Control No: 148335 ; Merck Canada Inc. Date of Preparation: December 12, 2013. http://www.merck.ca/assets/en/pdf/products/GRASTEK-PM_E.pdf
  • 27. C2. Warnings and Precautions s/l tablet: 2800 BAU Systemic allergic reactions, including life- threatening anaphylactic shock and severe local allergic reactions, have been observed in patients receiving 2800 BAU, and may require emergency administration of epinephrine, antihistamines, bronchodilators or systemic corticosteroids. PRODUCT MONOGRAPH: GRASTEK™ Standardized Allergenic Extract, Timothy Grass (Phleum pratense) ; Sublingual Tablet, 2800 BAU; Allergy Immunotherapy table; Submission Control No: 148335 ; Merck Canada Inc. Date of Preparation: December 12, 2013. http://www.merck.ca/assets/en/pdf/products/GRASTEK-PM_E.pdf
  • 28. An Immunotherapy-Shot Alternative for Respiratory Allergies? Lin and colleagues reviewed the entire literature on this topic, accepting only studies that provided good scientific data. Sixty-three studies that included 5131 persons aged 4-74 years received sublingual tablets of 1 or more allergens or placebo, which were taken on a maintenance basis at daily or weekly intervals over extended periods ranging from 3 months to 5 years. The principal efficacy outcomes were symptom improvement, need for additional (rescue) medication, and quality of life. Adverse events were included for safety. Local reactions were frequent, but anaphylaxis was not reported and presumably absent. The reviewers cautioned that their conclusions were limited by the great variations among studies in the type of immunotherapy used and its dose, frequency, and duration. 1. Nicholas Gross, MD, PhD. An Immunotherapy-Shot Alternative for Respiratory Allergies?. http://www.medscape.com/viewarticle/804816 2. Lin SY, Erekosima N, Kim JM, et al . Sublingual Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and Asthma: a Systematic Review JAMA. 2013;309:1278-1288 3. Nelson HS. Is sublingual immunotherapy ready for use in the United States? JAMA. 2013;309:1297-1298. 4. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis (including hay fever). Cochrane Summaries. February 16, 2011. http://summaries.cochrane.org/CD002893/sublingual-immunotherapy-for-allergic-rhinitis-including-hay-fever Accessed April 30, 2013.
  • 29. s/l tablet: 2800 BAU Safety Adults • In pooled analyses of data from children and adolescents, most adverse events occurred within the first 1 to 2 weeks of treatment, and the highest percentage of adverse events occurred on day 1. Medscape Medical News: Grastek Recommended by FDA Panel for Timothy Grass Allergy; FDA Allergenic Products Committee Meeting. December 12, 2013 http://www.medscape.com/viewarticle/817771
  • 30. C3. Warnings and Precautions s/l tablet: 2800 BAU The first tablet of 2800 BAU must be taken at the physician’s office under medical supervision and the patient must be monitored for at least 30 minutes. Extra precautions must be taken while treating pediatric patients, including: each administration of GRASTEK™ must be given under direct adult supervision for at least 30 minutes PRODUCT MONOGRAPH: GRASTEK™ Standardized Allergenic Extract, Timothy Grass (Phleum pratense) ; Sublingual Tablet, 2800 BAU; Allergy Immunotherapy table; Submission Control No: 148335 ; Merck Canada Inc. Date of Preparation: December 12, 2013. http://www.merck.ca/assets/en/pdf/products/GRASTEK-PM_E.pdf
  • 31. s/l tablet: 2800 BAU Safety Adults • The treatment-emergent adverse events that were reported most frequently were: 1. oral pruritus (26.7%, MK-7243; 3.5%, placebo) 2. throat irritation (22.6%, MK-7243; 2.8%, placebo) 3. ear pruritus (12.5%, MK-7243; 1.1%, placebo) 4. mouth edema (11.1%, MK-7243; 0.8%, placebo). Medscape Medical News: Grastek Recommended by FDA Panel for Timothy Grass Allergy; FDA Allergenic Products Committee Meeting. December 12, 2013 http://www.medscape.com/viewarticle/817771
  • 32. s/l tablet: 2800 BAU Safety Child • The treatment-emergent adverse events that were reported most frequently were: 1. oral pruritus (24.4%, MK-7243; 2.1%, placebo) 2. throat irritation (21.3%, MK-7243; 2.5%, placebo) 3. tongue pruritus (9.2%, MK-7243; 0.9%, placebo) 4. mouth edema (9.8%, MK-7243; 0.2%, placebo). Medscape Medical News: Grastek Recommended by FDA Panel for Timothy Grass Allergy; FDA Allergenic Products Committee Meeting. December 12, 2013 http://www.medscape.com/viewarticle/817771
  • 33. Sublingual immunotherapy for allergic rhinitis (including hay fever) Allergic rhinitis is characterised by red, itchy eyes, a blocked and runny nose, and sneezing. The most common causes of allergic rhinitis are different pollens (grass and tree), house dust mites, mould and animal dander. Allergic rhinitis can be intermittent (such as hay fever) or persistent (all year round). Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis (including hay fever). Cochrane Summaries. February 16, 2011. : http://summaries.cochrane.org/CD002893/sublingual-immunotherapy-for-allergic-rhinitis-including-hay-fever#sthash.3xD98siS.dpuf
  • 34. Sublingual immunotherapy for allergic rhinitis (including hay fever) The treatment of allergic rhinitis depends on its severity and duration, and is usually based on the use of antihistamines and nasal corticosteroids. If these drugs cannot control symptoms immunotherapy is recommended. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis (including hay fever). Cochrane Summaries. February 16, 2011. : http://summaries.cochrane.org/CD002893/sublingual-immunotherapy-for-allergic-rhinitis-including-hay-fever#sthash.3xD98siS.dpuf
  • 35. Sublingual immunotherapy for allergic rhinitis (including hay fever) Immunotherapy involves the administration of gradually increasing doses of the allergen over a period of time to desensitise the patient. It is the only known treatment that modifies the immune response and treats the cause rather than the symptoms. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis (including hay fever). Cochrane Summaries. February 16, 2011. : http://summaries.cochrane.org/CD002893/sublingual-immunotherapy-for-allergic-rhinitis-including-hay-fever#sthash.3xD98siS.dpuf
  • 36. Sublingual immunotherapy for allergic rhinitis (including hay fever) In reviewing 60 trials we found a significant reduction in symptom and medication scores in patients treated with sublingual immunotherapy compared to placebo. There were no serious adverse reactions reported in the included trials and no patient needed the use of adrenaline. This updated Cochrane Review therefore reinforces the conclusions of the earlier review in confirming the efficacy and safety of sublingual immunotherapy. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis (including hay fever). Cochrane Summaries. February 16, 2011. : http://summaries.cochrane.org/CD002893/sublingual-immunotherapy-for-allergic-rhinitis-including-hay-fever#sthash.3xD98siS.dpuf
  • 37. Sublingual Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and Asthma: Our review found moderate strength in the evidence to support the use of sublingual immunotherapy for allergic rhinitis and asthma. This indicates moderate confidence that the evidence reflects a true efficacy. There were limitations in the standardization of adverse event reporting, but no life-threatening adverse events were noted. Lin S.Y.; Sublingual Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and AsthmaA Systematic Review JAMA. 2013;309(12):1278-1288. doi:10.1001/jama.2013.2049.[March 27, 2013, Vol 309, No. 12 ]
  • 38. An Immunotherapy-Shot Alternative for Respiratory Allergies? Lin and colleagues reviewed the entire literature on this topic, accepting only studies that provided good scientific data. Sixty-three studies that included 5131 persons aged 4-74 years received sublingual tablets of 1 or more allergens or placebo, which were taken on a maintenance basis at daily or weekly intervals over extended periods ranging from 3 months to 5 years. The principal efficacy outcomes were symptom improvement, need for additional (rescue) medication, and quality of life. Adverse events were included for safety. There were 13 studies of allergic asthma, of which 9 provided "strong evidence...that sublingual immunotherapy improved symptoms" and decreased the need for supplemental medications. 1. Nicholas Gross, MD, PhD. An Immunotherapy-Shot Alternative for Respiratory Allergies?. http://www.medscape.com/viewarticle/804816 2. Lin SY, Erekosima N, Kim JM, et al . Sublingual Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and Asthma: a Systematic Review JAMA. 2013;309:1278-1288 3. Nelson HS. Is sublingual immunotherapy ready for use in the United States? JAMA. 2013;309:1297-1298. 4. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis (including hay fever). Cochrane Summaries. February 16, 2011. http://summaries.cochrane.org/CD002893/sublingual-immunotherapy-for-allergic-rhinitis-including-hay-fever Accessed April 30, 2013.
  • 39. An Immunotherapy-Shot Alternative for Respiratory Allergies? Lin and colleagues reviewed the entire literature on this topic, accepting only studies that provided good scientific data. Sixty-three studies that included 5131 persons aged 4-74 years received sublingual tablets of 1 or more allergens or placebo, which were taken on a maintenance basis at daily or weekly intervals over extended periods ranging from 3 months to 5 years. The principal efficacy outcomes were symptom improvement, need for additional (rescue) medication, and quality of life. Adverse events were included for safety. 36 studies of allergic rhinoconjunctivitis provided "moderate evidence" that supported a decrease in symptoms and improvements in disease-specific quality of life. 1. Nicholas Gross, MD, PhD. An Immunotherapy-Shot Alternative for Respiratory Allergies?. http://www.medscape.com/viewarticle/804816 2. Lin SY, Erekosima N, Kim JM, et al . Sublingual Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and Asthma: a Systematic Review JAMA. 2013;309:1278-1288 3. Nelson HS. Is sublingual immunotherapy ready for use in the United States? JAMA. 2013;309:1297-1298. 4. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis (including hay fever). Cochrane Summaries. February 16, 2011. http://summaries.cochrane.org/CD002893/sublingual-immunotherapy-for-allergic-rhinitis-including-hay-fever Accessed April 30, 2013.
  • 40. Immunotherapy by allergen injections for seasonal allergic rhinitis ('hay fever') Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Immunotherapy by allergen injections for seasonal allergic rhinitis ('hay fever'). Cochrane Summaries. January 21, 2009 http://summaries.cochrane.org/CD001936/immunotherapy-by-allergen-injections-for-seasonal-allergic-rhinitis-hay-fever#sthash.7BSYsB2K.dpuf
  • 41. How long is the patient advised to wait after immunotherapy ? Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Immunotherapy by allergen injections for seasonal allergic rhinitis ('hay fever'). Cochrane Summaries. January 21, 2009 http://summaries.cochrane.org/CD001936/immunotherapy-by-allergen-injections-for-seasonal-allergic-rhinitis-hay-fever#sthash.7BSYsB2K.dpuf
  • 42. Time to Onset of Systemic Reactions with Allergen Immunotherapy Greineder DK. J Allergy Clin Immunol 1996; 98:S330-S334. [Data from Matloff et al. Allergy Proc 1993; 14:347-50.] Time not recorded 10% 2-24 hours 8% 60-120 minutes minimum 2% 0-30 minutes 72% 30-60 minutes 8% Note: based on this, patients should be advised that they must wait 30 minutes in the clinic after receiving subcutaneous immunotherapy
  • 43. Immunotherapy for seasonal allergic rhinitis SCIT vs SLIT Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Immunotherapy by allergen injections for seasonal allergic rhinitis ('hay fever'). Cochrane Summaries. January 21, 2009 http://summaries.cochrane.org/CD001936/immunotherapy-by-allergen-injections-for-seasonal-allergic-rhinitis-hay-fever#sthash.7BSYsB2K.dpuf Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis (including hay fever). Cochrane Summaries. February 16, 2011. : http://summaries.cochrane.org/CD002893/sublingual-immunotherapy-for-allergic-rhinitis-including-hay-fever#sthash.3xD98siS.dpuf
  • 44. Vial #0 1:1000 Vial #1 1:100 Vial #2 1:10 Vial #3 1:1 Dose mL Dose mL Dose mL Dose mL 1 0.10 6 0.10 11 0.05 17 0.05 2 0.20 7 0.20 12 0.10 18 0.07 3 0.30 8 0.30 13 0.20 19 0.10 4 0.40 9 0.40 14 0.30 20 0.15 5 0.50 10 0.50 15 0.40 21 0.20 16 0.50 22 0.25 ***Hollister-Stier Extract*** Note: Record all injections in the treatment record. Note: This dosage chart is offered as a suggested schedule. However, the degree of sensitivity varies in many individuals. In these cases, the size of the dose and intervals between doses may have to be adjusted and should be regulated by the patient’s tolerance and reaction. Treatment is normally started with the weakest dilution in the set. Beginning with dose #1 as listed in the schedule. Doses should be administered at weekly or twice-weekly (at least two days apart) intervals while working up. The maintenance level is […] 23 0.30 24 0.35 25 0.40 26 0.45 27 0.50 Gradually increase intervals to monthly maintenance. *Please read text to left* Subcutaneous IT: Sample Dose Chart Dr.: Patient: Content: Lot No.: Expiry Date: This is a suggested dose chart only. Please read the instructions before commencing desensitization. Observe patients for 30 minutes after each injection. Check extract dilution and dose: Check the patient for local or systemic reaction(s) to previous injection.
  • 45. Timothy Grass Pollen Allergen Extract s/l tablet: 2800 BAU • The recommended dose is 1 sublingual tablet daily; patients begin treatment 12 weeks before and continue throughout the grass pollen season. • The first dose is given at the healthcare provider's office; all other doses are taken at home. The tablet dissolves in less than 10 seconds, according to the company briefing. Medscape Medical News: Grastek Recommended by FDA Panel for Timothy Grass Allergy; FDA Allergenic Products Committee Meeting. December 12, 2013 http://www.medscape.com/viewarticle/817771
  • 46. Sublingual Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and Asthma s/l pill Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis (including hay fever). Cochrane Summaries. February 16, 2011. : http://summaries.cochrane.org/CD002893/sublingual-immunotherapy-for-allergic-rhinitis-including-hay-fever#sthash.3xD98siS.dpuf
  • 47. SCIT vs SLIT SCIT = subcutaneous immunotherapy SLIT = sublingual immunotherapy
  • 48. 1 2 3 4 5 6 7 8 9 10 + 1 2 3 4 5 6 7 8 9 10 +
  • 49. http://www.ec.gc.ca/cas-aqhi/default.asp?lang=En&n=9E5D28AD-1 Environment Canada
  • 50. http://www.bcairquality.ca/readings/index.html
  • 51. Abelsohn A., Stieb DM; Health effects of outdoor air pollution; Approach to counseling patients using the Air Quality Health Index; Clinical Review; Can Fam Physician 2011;57:881-7 Health effects of outdoor air pollution
  • 52. Air Quality Health Index (AQHI) Abelsohn A., Stieb DM; Health effects of outdoor air pollution; Approach to counseling patients using the Air Quality Health Index; Clinical Review; Can Fam Physician 2011;57:881-7
  • 53. Air Quality Health Index (AQHI) Abelsohn A., Stieb DM; Health effects of outdoor air pollution; Approach to counseling patients using the Air Quality Health Index; Clinical Review; Can Fam Physician 2011;57:881-7